drugset / Trial / NCT01402479

An Open-labeled Trial of Ramipril in Patients With Migraine

NCT01402479

Phase 2 Completed 50 enrolled Seoul National University Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.

Timeline

Start
2004-10
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ramipril Small molecule 2.5 mg

Indications